HIF1A and neoplasm: Through preclinical studies using a pharmacological HIF-1 inhibitor, YC-1, a dominant negative mutant of HIF-1α, or short hairpin/short interfering RNA against HIF-1α, it has been extensively confirmed that inhibition of intratumoral HIF-1 activity delayed tumor growth after radiation therapy [9-11,65,66].